Grant: Master's Award: Canada Graduate Scholarships
McGill University
$27,000.00
Identifying cell-cell interactions and mutation specific processes driving pathogenesis in RASopathy associated hypertrophic cardiomyopathy: towards novel therapeutic approaches
FY 2024-25
Summary
RASopathies are rare genetic disorders caused by overactivation of a pathway in our cells called RAS/MAPK. Genetic defects in this mechanism cause diseases of many organs, including the heart. My doctoral research focuses on the thickening of heart walls, or hypertrophic cardiomyopathy (HCM), which is particularly observed when the RAF1 gene is mutated. The RAF1 mutation S257L is recurrent in most patients with severe, early-onset cases with poor prognosis and mortality reaching up to 80%.Until recently, treatments for RASopathies only addressed symptoms. However, my host laboratory has successfully used trametinib, originally used for cancer treatment, to treat HCM by slowing down the RAS/MAPK mechanism. In my project, I will create laboratory models to better understand how this RAF1 mutation causes HCM and how to improve its treatment.We have derived stem cells from these patients and can transform them into heart cells: I will focus on cardiac muscle cells (cardiomyocytes), supporting cells (cardiac fibroblasts), and cells lining blood vessels (cardiac endothelial cells). Co-culturing them will clarify their interactions and help us identify factors that lead to cell enlargement and wall thickening. Using trametinib, we will model treatment effects and explore other RAS/MAPK-inhibiting drugs.I will also develop a mouse model with this mutation, as no such model currently exists. Given its clinical relevance, this model will enable more representative studies of the mutation.These two models will allow us to examine cell size, strength, and mechanical function, and molecular changes in HCM. Better understanding these mechanisms will allow us to identify potential new targets for therapies and improve the clinical management of this disease and reduce mortality.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
529621
Name
Medouni Anaïs
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Identifying cell-cell interactions and mutation specific processes driving pathogenesis in RASopathy associated hypertrophic cardiomyopathy: towards novel therapeutic approaches
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Hypertrophic Cardiomyopathy; Induced Pluripotent Stem Cells; Mek Inhibition; Murine Model; Rasopathies; Single Nucleus Rna Sequencing
Abstract
RASopathies are rare genetic disorders caused by overactivation of a pathway in our cells called RAS/MAPK. Genetic defects in this mechanism cause diseases of many organs, including the heart. My doctoral research focuses on the thickening of heart walls, or hypertrophic cardiomyopathy (HCM), which is particularly observed when the RAF1 gene is mutated. The RAF1 mutation S257L is recurrent in most patients with severe, early-onset cases with poor prognosis and mortality reaching up to 80%.Until recently, treatments for RASopathies only addressed symptoms. However, my host laboratory has successfully used trametinib, originally used for cancer treatment, to treat HCM by slowing down the RAS/MAPK mechanism. In my project, I will create laboratory models to better understand how this RAF1 mutation causes HCM and how to improve its treatment.We have derived stem cells from these patients and can transform them into heart cells: I will focus on cardiac muscle cells (cardiomyocytes), supporting cells (cardiac fibroblasts), and cells lining blood vessels (cardiac endothelial cells). Co-culturing them will clarify their interactions and help us identify factors that lead to cell enlargement and wall thickening. Using trametinib, we will model treatment effects and explore other RAS/MAPK-inhibiting drugs.I will also develop a mouse model with this mutation, as no such model currently exists. Given its clinical relevance, this model will enable more representative studies of the mutation.These two models will allow us to examine cell size, strength, and mechanical function, and molecular changes in HCM. Better understanding these mechanisms will allow us to identify potential new targets for therapies and improve the clinical management of this disease and reduce mortality.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Medouni, Anaïs
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~